On May 25, 2022, Novavax announced it was participating in a stage of the COVID-19 Vaccine Schedule Combinations (Com-COV) program initiated by the University of Oxford and supported by the UK Vaccine Taskforce and the National Institute for Health and Care Research. Novavax’ protein-based COVID-19 vaccine, NVX-CoV2373, was one of two COVID-19 vaccines studied as a third dose booster in adolescents aged 12 through 15 years to evaluate the potential use of vaccines from different manufacturers to achieve immune protection against COVID-19.

This stage of the investigator-initiated Phase 2 single-blind, randomized clinical trial analyzed reactogenicity and immune system responses to new combinations of vaccines in approximately 380 participants. All participants had completed a two-dose schedule of the Pfizer-BioNTech vaccine at least three months before joining the trial. A third dose of either NVX-CoV2373 or the Pfizer-BioNTech vaccine was administered as part of the trial.